Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Candel reported a Q2 net loss of $38.9 million, reflecting increased R&D and manufacturing spend, but ended the quarter with $201.6 million in cash to fund operations into Q1 2028. The company is on track to submit a BLA for aglatimagene in Q4 2026 for localized prostate cancer, following the publication of pivotal Phase 3 data in The Lancet Oncology that showed a 39% improvement in disease-free survival.
Key figures
- Drug Name
- aglatimagene besadenovec
- Phase Of Trial
- Phase 3
- Runway
- Q1 2028
- Net loss
- 38900000
- Rd expenses
- 19800000
- Cash position
- 201600000
- Prostate cancer dfs improvement
- 39%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.